Drug Trial News

RSS

Redhill Biopharma announces completion of Phase 2/3 COVID-19 study of oral opaganib

RedHill Biopharma Ltd., a specialty pharma company that is a leader in the development of novel oral therapies for COVID-19, today announced that all treatment and follow-up has now been completed in the 475-patient global Phase 2/3 study with opaganib (ABC294640) in patients hospitalized with severe COVID-19 pneumonia (NCT04467840). Top-line results are expected in the coming weeks.

20 Jul 2021

Evaluation of a synthetic DNA SARS-CoV-2 vaccine INO-4800 using a nonhuman primate model

A new study published in Vaccine assesses the safety and efficacy of the synthetic DNA vaccine candidate INO-4800, delivered as a single or double dose regime.

18 Jul 2021

Combination of investigational therapeutic and chemotherapy shows promise for AML treatment

The investigational therapeutic ficlatuzumab in combination with chemotherapy showed signs of clinical efficacy in patients with relapsed/refractory acute myeloid leukemia.

16 Jul 2021

Water-soluble vitamin E compounds directly inhibit SARS-CoV-2 replication and synergize with remdesivir

Researchers in the United States have shown that water-soluble derivatives of vitamin E (α-tocopherol) exhibit potent antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

15 Jul 2021

COVID-19 vaccine candidate that can be produced in yeast proves effective in macaques

Researchers in the United States have designed a modular protein subunit vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that elicited a strong immune response in macaques and prevented the animals from developing coronavirus disease 2019 (COVID-19).

15 Jul 2021

Drug combination found to be safe and effective in malignant peritoneal mesothelioma patients

A phase II study led by researchers from The University of Texas MD Anderson Cancer Center found that treatment with atezolizumab and bevacizumab was well-tolerated and resulted in a 40% objective response rate in patients with advanced malignant peritoneal mesothelioma, a rare cancer in the lining of the abdomen.

14 Jul 2021

New OMV-based COVID-19 vaccine candidate proves effective in mice

Researchers in Italy have demonstrated the efficacy of using modified outer membrane vesicles (OMVs) as a vaccine to protect against coronavirus disease 2019 (COVID-19) in an animal model.

14 Jul 2021

Dying patients with rare diseases struggle to get experimental therapies

At 15, Autumn Fuernisen is dying. She was diagnosed at age 11 with a rare degenerative brain disorder that has no known cure or way to slow it down: juvenile-onset Huntington's disease.

14 Jul 2021

What is behind the inconsistent results of COVID-19 clinical trials?

“Most clinical studies of antiviral drugs for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) have failed to observe a statistically significant effect, which may be due to poor designs of clinical trials.”

12 Jul 2021

Durable antibody response at least 8 months following vaccination with J&J COVID vaccine

A recent study by a team of scientists at Beth Israel Deaconess Medical Center and Janssen Vaccines & Prevention has demonstrated that humoral and cellular immunity elicited by the coronavirus disease 2019 (COVID-19) vaccine Ad26.COV2.S remains active for at least eight months.

9 Jul 2021

Study finds slight improvement in reporting adverse effects in drug trials over the last 17 years

Researchers, including academics from the University of York, analyzed systematic reviews of 1,200 Randomized Controlled Trials (RCTs) to assess whether reporting had improved over time.

9 Jul 2021

Antibiotic clofoctol shows potential against SARS-CoV-2

In a recent study, a group of French researchers aimed to reduce the regulatory preclinical development steps that potential candidates are normally subjected to.

5 Jul 2021

Two chemoattenuated PfSPZ malaria vaccines provide strong and lasting protection

A team of researchers recently optimized regimens for CVac, wherein aseptic, purified, cryopreserved, and infectious PfSPZ were inoculated and mixed with PYR and CQ.

5 Jul 2021

Study says mRNA COVID vaccines are effective against Lambda variant

Researchers in the United States have conducted a study suggesting that the coronavirus disease 2019 (COVID-19) vaccines that are currently being rolled out in many countries should be effective against the C.37 lineage (lambda variant) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

5 Jul 2021

Scientists identify natural SARS-CoV-2 super immunity against 23 variants

The antibodies are capable of neutralizing a wide range of SARS-CoV-2 variants even at sub-nanomolar concentrations. In addition, the combinations of these antibodies reduce the risk of generating escape mutants in vitro. The study is published in the journal Science.

5 Jul 2021

Novavax COVID-19 vaccine demonstrates ~90% efficacy against SARS-CoV-2

The findings reveal that the two-dose regimen of the vaccine is almost 90% effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Moreover, the vaccine shows high efficacy against the B.1.1.7 variant (Alpha) of SARS-CoV-2.

5 Jul 2021

Janssens’ COVID-19 vaccine effective against SARS-CoV-2 Delta variant

Researchers in the Netherlands have conducted a study showing that Janssen’s Ad26.COV2.S coronavirus disease 2019 (COVID‐19) vaccine was effective against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among eight individuals.

4 Jul 2021

Novel candidate malaria vaccine confers high levels of durable protection

Two U.S. Phase 1 clinical trials of a novel candidate malaria vaccine have found that the regimen conferred unprecedentedly high levels of durable protection when volunteers were later exposed to disease-causing malaria parasites.

30 Jun 2021

Moderna's COVID vaccine effective against emerging variants including Delta

Researchers in the United States have analyzed the neutralizing activity of Moderna’s mRNA-1273 vaccine against several variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

30 Jun 2021

Sanaria researchers make progress in the development of highly protective malaria vaccine

Researchers from Sanaria Inc. and the National Institutes of Health are making progress in the development of highly protective malaria vaccines.

30 Jun 2021

Previous
1
...
47
48
49
50
51
52
53
...
1143
Next

Drug Trial News

Redhill Biopharma announces completion of Phase 2/3 COVID-19 study of oral opaganib

Evaluation of a synthetic DNA SARS-CoV-2 vaccine INO-4800 using a nonhuman primate model

Combination of investigational therapeutic and chemotherapy shows promise for AML treatment

Water-soluble vitamin E compounds directly inhibit SARS-CoV-2 replication and synergize with remdesivir

COVID-19 vaccine candidate that can be produced in yeast proves effective in macaques

Drug combination found to be safe and effective in malignant peritoneal mesothelioma patients

New OMV-based COVID-19 vaccine candidate proves effective in mice

Dying patients with rare diseases struggle to get experimental therapies

What is behind the inconsistent results of COVID-19 clinical trials?

Durable antibody response at least 8 months following vaccination with J&J COVID vaccine

Study finds slight improvement in reporting adverse effects in drug trials over the last 17 years

Antibiotic clofoctol shows potential against SARS-CoV-2

Two chemoattenuated PfSPZ malaria vaccines provide strong and lasting protection

Study says mRNA COVID vaccines are effective against Lambda variant

Scientists identify natural SARS-CoV-2 super immunity against 23 variants

Novavax COVID-19 vaccine demonstrates ~90% efficacy against SARS-CoV-2

Janssens’ COVID-19 vaccine effective against SARS-CoV-2 Delta variant

Novel candidate malaria vaccine confers high levels of durable protection

Moderna's COVID vaccine effective against emerging variants including Delta

Sanaria researchers make progress in the development of highly protective malaria vaccine

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News